Stringent Global Regulatory Requirements to Hamper Market Growth
NEW YORK, Feb. 10, 2022 /PRNewswire/ -- The Canine Atopic Dermatitis Market value is set to grow by USD 319.37 million, progressing at a CAGR of 7.75% from 2021 to 2026, as per the latest report by Technavio
To know exact growth variance and the Y-O-Y growth rate Request a free sample report
The Increase in Pet Humanization to Support Market Growth:
The owners of pets look for good healthcare products and veterinary services to improve the health and lifespan of their pets. This is evident in both emerging as well as developed markets. Globally, pet owners are ensuring that the quality of ingredients and manufacturing standards of all pet care products are as good as those intended for and used by people. Pet owners belonging to the younger generation are making efforts to pamper their pets. The expectations and demands for pet wellness products are constantly increasing, which is driving the demand for drugs for the treatment of canine atopic dermatitis during the forecast period.
The Stringent Global Regulatory Requirements is Hindering Market Growth:
Manufacturers are required to follow the implemented stringent regulatory requirement to avoid consequences. Furthermore, the new animal drugs include an approved application before being imported from one country to another. The drug applications include approved new animal drug application (NADA), abbreviated NADA (ANADA), investigational new animal drug application (INAD), generic investigational new animal drug application (JINDA), conditional approval (CNADA), or index listing. Hence, the presence of such stringent regulations can hamper the demand for medications to treat canine atopic dermatitis during the forecast period.
Download Free sample Report for insights on the Drivers and Challenges that will help companies evaluate and develop growth strategies for 2022-2026.
Canine Atopic Dermatitis Market 2022-2026: Segmentation
For more insights on the market share and contribution of various regions & segments Request for a FREE sample now!
Canine Atopic Dermatitis Market 2022-2026: Scope
Our Canine Atopic Dermatitis Market report covers the following areas:
Canine Atopic Dermatitis Market 2022-2026: Vendor Analysis
The canine atopic dermatitis market is fragmented and the vendors are deploying growth strategies such as low pricing strategies and strengthening their customer base in local or regional markets to compete in the market. Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc. among others are some of the major market participants.
Subscribe to our "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.
Canine Atopic Dermatitis Market 2022-2026: Key Highlights
Related Reports:
Companion Animal Specialty Drugs Market by Product and Geography - Forecast and Analysis 2021-2025: The companion animal specialty drugs market value is projected to grow by USD 2.80 billion at a CAGR of 5.20% during 2021-2025. To get more research insights: Download Our FREE Sample Report
Animal Growth Enhancers Market by Product and Geography - Forecast and Analysis 2021-2025: The animal growth enhancers market has the potential to grow by USD 4.63 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.81%. To get more research insights: Download Our Latest FREE Sample Report
Canine Atopic Dermatitis Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.75% |
Market growth 2022-2026 |
$ 319.37 million |
Market structure |
Fragmented |
YoY growth (%) |
4.03 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, UK, Brazil, Germany, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization preview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article